We wish to thank Daniel J. Sargent, PhD, and Sherry Breaux, MPH, for their critical reading of the article and helpful suggestions. We also thank Deedra Nicolet, MS, and Dean Margeson, MAS, for help with the data analysis. Above all, we are grateful to the patients, physicians, nurses, and data managers who participated in this trial.
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808
Article first published online: 31 DEC 2013
© 2013 American Cancer Society
Volume 120, Issue 7, pages 1010–1017, 1 April 2014
How to Cite
Kolitz, J. E., George, S. L., Benson, D. M., Maharry, K., Marcucci, G., Vij, R., Powell, B. L., Allen, S. L., DeAngelo, D. J., Shea, T. C., Stock, W., Bakan, C. E., Hars, V., Hoke, E., Bloomfield, C. D., Caligiuri, M. A., Larson, R. A. and For the Alliance for Clinical Trials in Oncology (2014), Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808. Cancer, 120: 1010–1017. doi: 10.1002/cncr.28516
The following institutions participated in the current study: Christiana Care Health Services Inc Community Clinical Oncology Program, Wilmington, DE (Stephen Grubbs, MD, supported by CA45418); Dana-Farber Cancer Institute, Boston, MA (Harold J. Burstein, MD, PhD, supported by CA32291); Dartmouth Medical School-Norris Cotton Cancer Center, Lebanon, NH (Konstantin Dragnev, MD, supported by CA04326); Duke University Medical Center, Durham, NC (Jeffrey Crawford, MD, supported by CA47577); Georgetown University Medical Center, Washington, DC (Minetta C. Liu, MD, supported by CA77597); Green Mountain Oncology Group Community Clinical Oncology Program, Bennington, VT (Herbert L. Maurer, MD, supported by CA35091); Illinois Oncology Research Association, Peoria, IL (John W. Kugler, MD, supported by CA35113); Monter Cancer Center of North Shore-Long Island Jewish Health Systems, Lake Success, NY (Daniel Budman, MD, supported by CA35279); Massachusetts General Hospital, Boston, MA (Jeffrey W. Clark, MD, supported by CA32291); Mount Sinai School of Medicine, New York, NY (Lewis R. Silverman, MD, supported by CA04457); Nevada Cancer Research Foundation Community Clinical Oncology Program, Las Vegas, NV (John A. Ellerton, MD, supported by CA35421); Rhode Island Hospital, Providence, RI (William Sikov, MD, supported by CA08025); Roswell Park Cancer Institute, Buffalo, NY (Ellis Levine, MD, supported by CA59518); Southeast Cancer Control Consortium Inc Community Clinical Oncology Program, Goldsboro, NC (James N. Atkins, MD, supported by CA45808); State University of New York Upstate Medical University, Syracuse, NY (Stephen L. Graziano, MD, supported by CA21060); The Ohio State University Medical Center, Columbus, OH (Clara D. Bloomfield, MD, supported by CA77658); University of California at San Diego, San Diego, CA (Barbara A. Parker, MD, supported by CA11789); University of California at San Francisco, San Francisco, CA (Charles J. Ryan, MD, supported by CA60138); University of Chicago, Chicago, IL (Hedy L. Kindler, MD, supported by CA41287); University of Illinois Minority-Based Community Clinical Oncology Program, Chicago, IL (David J. Peace, MD, supported by CA74811);University of Iowa, Iowa City, IA (Daniel A. Vaena, MD, supported by CA47642); University of Minnesota, Minneapolis, MN (Bruce A. Peterson, MD, supported by CA16450); University of Massachusetts Medical School, Worcester, MA (William V. Walsh, MD, supported by CA37135); University of Missouri/Ellis Fischel Cancer Center, Columbia, MO (Michael C. Perry, MD, supported by CA12046); University of Nebraska Medical Center, Omaha, NE (Apar Ganti, MD, supported by CA77298); University of Oklahoma, Oklahoma City, OK (Shubham Pant, MD, supported by CA37447); University of North Carolina at Chapel Hill, Chapel Hill, NC (Thomas C. Shea, MD, supported by CA47559); University of Vermont, Burlington, VT (Steven M. Grunberg, MD, supported by CA77406); Wake Forest University School of Medicine, Winston-Salem, NC (David D. Hurd, MD, supported by CA03927); Walter Reed Army Medical Center, Washington, DC (Brendan M. Weiss, MD, supported by CA26806); Washington University School of Medicine, St. Louis, MO (Nancy Bartlett, MD, supported by CA77440); Weill Medical College of Cornell University, New York, NY (John Leonard, MD, supported by CA07968); and Western Pennsylvania Cancer Institute, Pittsburgh, PA (John Lister, MD).
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.
See editorial on pages 940–1, this issue.
- Issue published online: 18 MAR 2014
- Article first published online: 31 DEC 2013
- Manuscript Accepted: 24 SEP 2013
- Manuscript Revised: 11 JUL 2013
- Manuscript Received: 5 MAY 2013
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.